RALEIGH–Salix Pharmaceuticals, Ltd (Nasdaq: SLXP)says that Arthur R. Kamm, Ph.D. has joined the Company as senior vice president, research and development and chief development officer.
Kamm has served in a consulting capacity with Salix since January 2003. Kamm has over 20 years of experience. Prior to joining Salix, Kamm was president, CEO and founder of A.R. Kamm Associates, Inc., a strategic-level consulting and medical product development service organization.
Prior to founding A.R. Kamm Associates, Kamm held the posts of vice president, clinical development and vice president, Zantac development for Glaxo, Inc.